ABSTRACT

Introduction: Anovulation is a common cause of infertility with poly cystic ovarian disease being the commonest.

Objective: To estimate the prevalence of various causes of anovulation in patients younger than 35 years of age attending infertility clinics and to ascertain the nature and extent of metabolic abnormalities and efficacy of therapy.

Materials and methods: Sixty cases of anovulatory infertility diagnosed by standard method were recruited for the study. Transvaginal sonography and hormonal profile like LH, FSH, Prolactin and Thyroid profile evaluated to establish the cause of anovulation. Menstrual history, Body Mass Index, Waist Hip ratio and presence of hirsutism, acanthosis nigricans were recorded. Metabolic parameters like lipid profile, OGTT and Glucose insulin ratio were also assessed. All parameters were reevaluated at 3 and 6 months of treatment and were statistically analyzed. Response to treatment in terms ovulation and pregnancy achieved was also analyzed.

Conclusion: Women with anovulatory infertility has shown good improvement to appropriate treatment.

Keywords: Infertility, Anovulation, Polycystic ovary syndrome, Clomiphen citrate.


Source of support: Nil

Conflict of interest: None

INTRODUCTION

Infertility is rapidly becoming one of the leading causes of visits to gynecology clinic by couples in the reproductive age group. Anovulation is among the most common causes of infertility.1 WHO has devised a classification scheme for women who do not ovulate, dividing them into three major groups, i.e. Group I: Hypothalamic pituitary failure, who have low to low-normal gonadotropin secretion with menopausal estradiol concentrations, like Kallmann’s syndrome, anorexia nervosa, etc; Group II: Hypothalamic pituitary dysfunction with estrogenic chronic anovulation, where individuals often exhibit elevated LH:FSH ratio, though gonadotropins are typically in the normal range, like PCOS; Group III: Hypergonadotropic hypogonadism where elevated levels of gonadotropins and hypoestrogenism is characteristic like premature ovarian failure. WHO Group II is by far the commonest group encountered in clinical practice. There are various methods available for assessing ovulation with advantages and pitfalls of each method. These methods are menstrual history, natural family planning methods, basal body temperature, serum progesterone concentration, urinary luteinizing hormone (LH) secretion monitoring, endometrial biopsy and transvaginal ultrasonography, though the only definitive proof of ovulation is pregnancy.

OBJECTIVES

1. To estimate the prevalence of various causes of anovulation in patients younger than 35 years of age attending infertility clinics.

2. To ascertain the nature and extent of metabolic abnormalities in such patients.

3. (i) To determine the efficacy of therapy in improving presenting complaints.

(ii) To determine the efficacy of therapy in improving metabolic abnormalities.

(iii) To determine the extent of ovulation and pregnancy achieved with treatment.

Study was conducted mainly on patients of poor to average socioeconomic status with a view to find various outcome in an average Indian population.

MATERIALS AND METHODS

This study was conducted at a tertiary care center from 01 Sep 2008 to 31 Mar 2010. The study population comprised of 60 women in the age group 21 to 34 years with anovulatory infertility. First 60 women identified with anovulatory infertility among a total of 167 attending infertility clinic were recruited in the study and each patient was studied for a period of 6 months. Patients were selected initially on the basis of menstrual history suggestive of anovulation (oligomenorrhea/amenorrhea), confirmed subsequently by transvaginal ultrasonographic follicular monitoring. Patients were also selected on the basis of TVUS when anovulation was found as cause of infertility even in presence of regular menses. A detailed menstrual, medical, surgical, drug and treatment history was taken. A thorough physical examination with particular reference to height, weight, body mass index (BMI), waist:Hip ratio, thyroid gland palpation, breast examination, body hair distribution, features of hyperinsulinemia (acanthosis nigricans) and gynecological examination was done. For anthropometric measurements, subjects were examined wearing light
Hyperprolactinemia:

4. Hyperthyroidism:

3. PCOS

1. Weight reduction
2. Insulin sensitizer—tab Metformin 500 mg TDS.
3. Hirsutism: Tab Eltroxin starting at 25 to 50 μg OD escalated as per requirement.
4. Hyperprolactinemia: Tab bromocriptine 2.5 mg OD-BD.

After achieving ovulation, controlled ovarian hyper stimulation (COH) was achieved with clomiphene citrate/ purified FSH and later ovulation trigger with injection human chorionic gonadotropin (hCG) was given. COH was done even if ovulation was not achieved after 3 cycles of treatment, as primary complaint of patients was infertility. This was followed by timed intercourse/intrauterine insemination (IUI). Change in menstrual history pattern in patients with abnormal menses, anthropometric parameters like waist:hip ratio; biochemical parameters like fasting glucose:insulin ratio and serum testosterone were measured at 3 and 6 months after treatment. Hormonal variables, like serum LH, FSH, LH:FSH ratio, prolactin, thyroid hormone levels, were measured at 3 and 6 months following treatment. The results thus obtained were analyzed statistically using students’ t-test.

RESULTS

A total of 60 patients who met the selection criteria were recruited in the study, out of the first 167 infertile patients attending the outpatient clinic. On further evaluation, 38 (63.3%) patients were diagnosed to have features of polycystic ovary syndrome, eight (13.3%) had hyperprolactinemia, six (10%) had hypothyroidism, two (3.3%) had hyperthyroidism and six (10%) had combination of above disorders. Our study found PCOS as dominating cause of anovulation among the infertile population with as high as 63.3% of cases.

Table 1 shows distribution of patients with menstrual irregularities and their response to treatment. Twenty-eight patients out of 39 with menstrual irregularities showed improvement following treatment. Around 71.4% of patients showed improved menses 6 months following treatment with weight reduction and metformin in PCO group and similar improvement found with appropriate treatment in other groups.

The various metabolic derangements found in PCOS patients are highlighted in Table 2. Current study showed a prevalence of 13.1% obesity (BMI ≥ 30) and 34.2% overweight individuals (overall 47.3%). Mean waist:hip ratio found in this study was 0.76, which is on the higher side of the normal levels. Abnormal lipid profile was found in 15.8% of PCO patients, without any improvement over 6 months of treatment. Our study found mean G:I ratio to be 2.957 indicating insulin resistance. G:I ratio as well as those showing abnormal OGTT did not show any appreciable improvement in the values after treatment. 13 (34%) patients showed free testosterone levels >60 ng/dl indicating hyperandrogenemia. There was a significant fall in 3 and 6 months post-treatment (60.5 ng/dl at 3 months and 54.60 ng/dl at 6 months following treatment vs 76.9 ng/dl before treatment). Table 3 shows that mean LH level was 12.092 IU/L and FSH level was 3.36 IU/l in this study. Mean LH: FSH ratio in this study was 3.799. Values ≥ 3.0 is considered to be a feature of PCOS. After treatment, LH levels showed a significant fall (10.951 vs 12.103 at 3 months, p-value 0.012 vs 12.103 at 6 months, p-value 0.010), the levels were however still high. There was a modest fall in LH:FSH ratio 3 and 6 months post-treatment which reached statistical significance (3.3 vs 3.7, p-value 0.012 at 3 months and 3.1 vs 3.7, p-value 0.010 at 6 months).

There were total eight patients presenting with hyperprolactinemia as cause of anovulatory infertility and two patients who had hyperprolactinemia with PCOS and one patient had coexistent hypothyroidism in current study. The basal prolactin levels ranged from 33.0 to 121.8 ng/ml (mean 57.08 ng/ml). Following bromocriptine treatment (2.5 mg BD daily), mean prolactin levels came down to 22.42 ng/ml at 3 months and 15.93 ng/ml at 6 months (Table 3). One patient with basal prolactin level 121.8 ng/ml
was subjected to MRI brain to rule out macroadenoma; however, the study showed no adenoma. After continued treatment with bromocriptine, the prolactin levels came down to within normal range in all the patients.

There were total eight patients presenting only with thyroid abnormalities as cause of anovulatory infertility and six patients had hypothyroidism with either PCOS or hyperprolactinemia in the current study. Out of total 14 patients with thyroid disorders, only two patients had hyperthyroidism, while rest of the patients presented with hypothyroidism. They responded well to appropriate treatment with improvement in symptoms as well as hormonal profile. Their hormonal profile values before and after treatment is shown in Table 3.

Table 4 shows ovulation study in patients studied. 78.9% of PCO patients and all other achieved ovulation during the study period. Table 5 shows the pregnancies achieved during 6 months follow-up period. A total of 19 pregnancies were achieved during this study. Ten out of 38 PCO patients became pregnant during the study. There were two spontaneous pregnancies with bromocriptine alone and two pregnancies with bromocriptine and ovulation induction with clomiphene followed by intrauterine insemination making total pregnancy rate achieved 50% among hyperprolactinemia patients. There was one spontaneous pregnancy during treatment with thyroxine only and two pregnancies with thyroxine and ovulation induction with clomiphene followed by intrauterine insemination in

### Table 1: Menstrual patterns among various groups of patients and response to treatment in such patterns

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Pattern</th>
<th>PCOS; n (%)</th>
<th>Hyperprolactinemia; n (%)</th>
<th>Thyroid disorders; n (%)</th>
<th>Combined; n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Irregular</td>
<td>28 (73.7)</td>
<td>3 (37.5)</td>
<td>5 (62.5)</td>
<td>3 (50.0)</td>
</tr>
<tr>
<td>2.</td>
<td>Regular</td>
<td>10 (26.3)</td>
<td>5 (62.5)</td>
<td>3 (37.5)</td>
<td>3 (50.0)</td>
</tr>
<tr>
<td>3.</td>
<td>Total</td>
<td>38</td>
<td>8</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>4.</td>
<td>Improved</td>
<td>20 (71.4)</td>
<td>2 (66.7)</td>
<td>4 (80)</td>
<td>2 (66.7)</td>
</tr>
<tr>
<td>5.</td>
<td>Not improved</td>
<td>8 (28.6)</td>
<td>1 (33.3)</td>
<td>1 (20.0)</td>
<td>1 (33.3)</td>
</tr>
</tbody>
</table>

### Table 2: Various metabolic disorders in patients of polycystic ovaries alone or in combination with other anovulatory disorders

<table>
<thead>
<tr>
<th>Group</th>
<th>Waist: hip ratio</th>
<th>Hirsutism</th>
<th>Acanthosis</th>
<th>Lipid profile</th>
<th>GTT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Increased (%)</td>
<td>Present</td>
<td>Absent</td>
<td>Normal</td>
<td>Abnormal</td>
</tr>
<tr>
<td></td>
<td>Not increased (%)</td>
<td>Present</td>
<td>Absent</td>
<td>Normal</td>
<td>Abnormal</td>
</tr>
<tr>
<td>PCOS; n (%)</td>
<td>7 (18.4)</td>
<td>31 (81.6)</td>
<td>23 (60.5)</td>
<td>12 (31.6)</td>
<td>32 (84.2)</td>
</tr>
<tr>
<td>Combined; n (%)</td>
<td>1 (16.7)</td>
<td>5 (83.3)</td>
<td>0 (0)</td>
<td>2 (33.3)</td>
<td>6 (100)</td>
</tr>
</tbody>
</table>

### Table 3: Comparative statistical analysis of various hormonal markers in this study

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>3 months</th>
<th>6 months</th>
<th>p-value (base vs 3 months)</th>
<th>p-value (base vs 6 months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LH (IU/l)</td>
<td>12.09 (38) ± 1.52</td>
<td>10.95 (38) ± 1.39</td>
<td>10.86 (38) ± 1.26</td>
<td>0.00</td>
<td>0.010</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td>3.36 (38) ± 0.78</td>
<td>3.26 (38) ± 0.78</td>
<td>3.10 (38) ± 0.70</td>
<td>0.628</td>
<td>0.620</td>
</tr>
<tr>
<td>LH:FSH</td>
<td>3.79 (38) ± 1.02</td>
<td>3.30 (38) ± 0.75</td>
<td>3.11 (38) ± 0.46</td>
<td>0.012</td>
<td>0.010</td>
</tr>
<tr>
<td>G:I ratio</td>
<td>2.96 (38) ± 0.68</td>
<td>2.97 (38) ± 0.58</td>
<td>2.86 (38) ± 0.85</td>
<td>0.853</td>
<td>0.839</td>
</tr>
<tr>
<td>Prolactin (mU/l)</td>
<td>57.08 (12) ± 19.88</td>
<td>22.42 (12) ± 5.85</td>
<td>15.93 (12) ± 2.17</td>
<td>0.000</td>
<td>0.001</td>
</tr>
<tr>
<td>TSH (mU/l)</td>
<td>24.54 (8) ± 14.92</td>
<td>12.57 (8) ± 5.11</td>
<td>5.98 (8) ± 2.07</td>
<td>0.0021</td>
<td>0.010</td>
</tr>
</tbody>
</table>

### Table 4: Ovulation achieved after treatment in various subset of patients

<table>
<thead>
<tr>
<th>S. no.</th>
<th>PCOS; n (%)</th>
<th>Hyperprolactinemia; n (%)</th>
<th>Thyroid disorders; n (%)</th>
<th>Combined; n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Achieved</td>
<td>30 (78.9)</td>
<td>8 (100)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>2.</td>
<td>Not achieved</td>
<td>8 (21.1)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

### Table 5: The number of pregnancies achieved in various subgroups

<table>
<thead>
<tr>
<th>S. no.</th>
<th>Pregnancy</th>
<th>PCOS; n (%)</th>
<th>Hyperprolactinemia; n (%)</th>
<th>Thyroid disorders; n (%)</th>
<th>Combined; n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Achieved</td>
<td>10 (26.3)</td>
<td>4 (50.0)</td>
<td>3 (37.5)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>2.</td>
<td>Not achieved</td>
<td>28 (73.7)</td>
<td>4 (50.0)</td>
<td>5 (62.5)</td>
<td>4 (66.7)</td>
</tr>
<tr>
<td>3.</td>
<td>Total</td>
<td>38</td>
<td>8</td>
<td>8</td>
<td>6</td>
</tr>
</tbody>
</table>
DISCUSSION

Anovulation is a common cause underlying infertility and is a common feature of various disorders like PCOS, thyroid disorders, etc. Overall 60 to 85% of such patients demonstrate ovary menstrual dysfunction, primarily oligo-amenorrhea, the remainder present with apparent eumenorrhea; although about 5% may demonstrate polymenorrhea. With treatment the length of menstrual cycle decreased from 45 to 120 days to 35 to 40 days, a 40% decrease in our study. In the study by Kolodziejczyk et al, the average length of cycle declined by 36%.2

True virilization is rare in PCOS, 70% of them complain of cosmetically disturbing hirsutism. Adams et al3 showed hirsutism in 55% of his patients. Our study showed hirsutism in 39.5% of PCOS patients. No change in hirsutism was seen after 6 months of treatment. 60 ng/dl of free serum testosterone was taken as the cutoff for hyperandrogenemia in this study. The free testosterone level ranged from 23.06 to 112.89 ng/dl, 13 (34%) patients showed levels >60 ng/dl indicating hyperandrogenemia. There was significant fall 3 and 6 months post-treatment (60.5 ng/dl >60 ng/dl indicating hyperandrogenemia. There was significant fall 3 and 6 months post-treatment (60.5 ng/dl at 3 months and 54.60 ng/dl at 6 months following treatment vs 76.9 ng/dl before treatment). Similar results were found by Hahn et al.4 The prevalence of obesity in PCOS women has been reported to be a little more than 50% of cases.5 Our study found 47.3% overweight patients among PCOS subgroup. Waist:hip ratio >0.85 is generally considered a marker of insulin resistance.5 Eight patients only had raised waist:hip ratio in our study. Waist:hip ratio was significantly higher in PCOS women than in control women in Legro et al study.6 A ratio of fasting glucose (G) to fasting insulin (I) has been qualified as a simple and useful predictor of insulin resistance in women with PCOS. A fasting G:I ratio (cutoff value <4.5) provided the best combination of sensitivity (95%) and specificity (84%) as well as the best positive predictive value (87%) and negative predictive value (94%) as a screening test for predicting insulin resistance in PCOS. The glucose-stimulated parameters obtained from the OGTT, although sensitive, displayed less specificity than fasting insulin and/or the fasting G:I ratio.6 Insulin resistance and the resulting hyperinsulinemia contribute to the reproductive abnormalities in PCO women. There was no significant rise in fasting G:I ratio after 6 months of treatment in our study. Trolle et al too found no significant improvement in their study.7 Present study did not find any improvement in insulin sensitivity possibly because of less number of obese individuals affecting overall results. All women with PCOS are at increased risk of developing impaired glucose tolerance and overt type 2 diabetes mellitus due to underlying insulin resistance. In Legro et al study IGT was found in 31% of women with PCOS and diabetes in 7.5%. In nonobese, these figures were 10.3 and 1.5%.6 Present study found abnormal OGTT in four PCOS patients and one with combination disorders, which showed no improvement over 6 months treatment, probably due to short period of observation. Pasquali et al8 demonstrated improvement in carbohydrate metabolism in his study over a period of 2 years, in comparison to our studies of 6 months duration. A spectrum of abnormal lipid and lipoprotein profiles may be found in patients with PCOS; characteristically patients have raised cholesterol, triglycerides, LDL and decreased HDL and Apo A1 levels. These findings, however, are highly variable and depend on the obesity status, diet and ethnicity of the population studied. Yilmaz et al found no positive impact on serum lipids in their 6 months study of PCOS patients,9 similar to our study.

LH and FSH levels were measured and LH levels (mean LH level: 12.092 IU/l) were found to be raised in all PCOS patients in this study. Normal levels in early follicular phase 6.5 IU/l, mid-follicular phase 5.0 IU/l, late follicular phase 7.2 IU/l.10 Nestler et al showed a significant reduction in basal levels of LH with metformin therapy (from 8.5 mIU/l to 2.8 mIU/ml) in both obese as well as lean PCOS patients.11 Our study did not show such a fall in LH levels probably due to less number of individuals achieving weight reduction over 6 months affecting both G:I ratio as well as LH levels.

Follicular maturation (follicles >15 mm) was assessed during the study period. 78.9% of PCOS patients, all patients of thyroid disorders, hyperprolactinemia and combination disorders achieved ovulation following treatment. Follicular maturation was seen by TVUS starting from day 10 of the menstrual cycle. Pirwani et al showed improvement in ovulation ranging from 40 to 90%.12 There were two (5.5%) spontaneous pregnancies following metformin treatment in PCOS group. Velazquez et al described 11% spontaneous pregnancies in his study.13 Rest 36 patients underwent ovulation induction with clomiphene citrate followed by timed intercourse (TI) or intrauterine insemination (IUI). There were eight pregnancies (22.2%) following ovulation induction with TI/IUI, making an overall pregnancy rate 26.3%. Results could have been better if the study was for a longer duration. George et al achieved overall pregnancy rate of 16.7% in 27 patients who were given metformin 1,500 mg/day in divided doses for 6 months.14 Hyperprolactinemia commonly occurs in the absence of galactorrhoea (66%), which may result from inadequate estrogenic or prostaglational priming of breast.1 63.6%
(total 7) of the patients in our study had galactorrhea at the
time of presentation, while 36.4% (4 patients) did not have
galactorrhea and pregnancy achieved in this group is 50%.
Pepperell et al had found 16 (80%) out of 20 patients of
hyperprolactinemia to be having clinical galactorrhea. Basal
prolactin levels in their study ranged from 19.0 to 93.2 ng/ml
and ovulation achieved in 17 (85%) of the 20 patients
studied and pregnancy achieved in 14 (70%).15

Krass et al found menstrual irregularities in 23 to 25%
of patients with thyroid disorders in their study,
oligomenorrhea was found to be commonest manifestation.16
In our study, six (75%) of these patients reported improved
cycles after 6 months of treatment. There was a significant
drop in TSH levels with thyroxine associated with clinical
improvement in the form of ovulation. Though the TSH
levels showed a significant fall following treatment, the
mean levels were still high (5.986 at 6 months); this was
probably due to a few patients with initial very high levels
affecting overall figures. Our pregnancy rate achieved in
this group is 21%. Oravec et al reported pregnancy rates
following thyroxine replacement therapy in infertile women
with ovulatory dysfunction and hypothyroidism up to 64%.17
Becker et al showed overall and spontaneous pregnancy
rates to be highest among women with normal TSH levels
following treatment.18

CONCLUSION

Anovulation is a common cause of female infertility.
Polycystic ovary syndrome by far the commonest underlying
factor. It is associated with a number of metabolic and
endocrinological abnormalities principally hyperinsulinemia
and hyperandrogenism. Metformin improves menstrual
cyclicity, follicular maturation and ovulation rates in PCOS
patients besides improving the metabolic parameters which
is of great significance in preventing the long-term
consequences. Dopamine agonists like bromocriptine can
correct hormonal and ovulatory dysfunction associated with
hyperprolactinemia. Appropriate treatment of thyroid
disorders in form of thyroxine replacement in hypothyroid
and antithyroid drugs in hyperthyroid individuals can
improve menstrual and ovulatory disturbances in such
patients.

Success rate of treatment is much higher in patients with
anovulatory infertility in comparison to other causes of
female infertility. Management of such cases can easily be
handled by gynecologists at peripheral centers with basic
infrastructure.

Findings of this study in respect of various anthropo-
metric, metabolic and endocrinological parameters as well
as their response to treatment in this subset of patients,
require further evaluation by a larger and long-term study
in this socioeconomic and ethnic group of population.

REFERENCES

1. Speroff L, Fritz MA. Clinical gynecological endocrinology and
2. Kolodziejczyk B. Metformin decreases hyperandrogenism and
hyperinsulinemia in women with PCOS. Fertil Steril 2000;73:
6-12.
3. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries
in women with anovulation and idiopathic hirsutism. BMJ 1986;
293:355-59.
4. Hahn S, Benson S, Elsenbruch S, Pleger K, Tan S, Mann K,
et al. Metformin treatment of polycystic ovary syndrome
improves health-related quality-of-life, emotional distress and
5. Korhonen S, Hippeläinen M, Niskanen L, Vanhala M,
Saarikoski S. Relationship of the metabolic syndrome and
obesity to polycystic ovary syndrome: A controlled, population-
predictions of the risk for type 2 diabetes mellitus and impaired
glucose tolerance in polycystic ovary syndrome: A prospective,
controlled study in 254 affected women. J Clin Endocrinol Metab
1999;84:165-74.
7. Trolle B, Flyvbjerg A, Kesmodel U, Lauszuus FF. Efficacy of
metformin in obese and non-obese women with polycystic ovary
syndrome: A randomized, double-blinded, placebo-controlled
treatment with metformin added to hypocaloric diet on body
composition, fat distribution, and androgen and insulin levels
in abdominally obese women with and without the polycystic
9. Yilmaz M, Bukan N, Ayvaz G, Karakoç A, Törüner F, Çakir N,
Arslan M. The effects of rosiglitazone and metformin on
oxidative stress and homocysteine levels in lean patients with
Luteinizing hormone receptors in ovarian follicles of patients
with polycystic ovarian disease. J Clin Endocrinol Metab
11. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary
syndrome respond to insulin reduction with decreases in ovarian
P450c17 activity and serum androgens. J Clin Endocrinol Metab
1997;82:4075-79.
12. Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of the
insulin sensitizing drug metformin on ovarian function, follicular
growth and ovulation rate in obese women with oligomenorr-
in polycystic ovary syndrome reduces hyperinsulinemia, insulin
resistance, hyperandrogenemia, and systolic blood pressure,
while facilitating normal menses and pregnancy. Metabolism
1994;43:647-54.
14. George SS, George K, Irwin C, Job V, Selvakumar R,
Jeyaseelan V, Seshadri MS. Sequential treatment of metformin
and clomiphene citrate in clomiphene-resistant women with
polycystic ovary syndrome: A randomized, controlled trial. Hum

ABOUT THE AUTHORS

Geetu Bhandoria
Major, Department of Obstetrics and Gynecology, Armed Forces Medical College, Pune, Maharashtra, India

Samar Rudra (Corresponding Author)
Professor, Department of Obstetrics and Gynecology, MM Institute of Medical Science and Research, Rohtak, Haryana, India, e-mail: rudra_samar@yahoo.co.in